A phase 1 study of D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, as monotherapy in patients with KRAS G12C-mutated solid tumors

被引：0
|
作者：
Cho, Byoung Chul
Lu, Shun
Lee, Myung Ah
Song, Zhengbo
Park, John
Lim, Sun Min
Li, Ziming
Zhao, Jun
Richardson, Gary
Zhang, Yanqiao
Zhang, Jun
Liu, Anwen
Chen, Cheng
Wang, Jia
Lu, Jingtao
Rui, Haopeng
Chen, Qian
Wang, Hui
Zhang, Jing
Chen, Zhi Jian
Mok, Tony
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT117
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT117
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I/II study of D3S-001, a second generation KRAS G12C inhibitor in advanced/metastatic solid tumors with KRAS G12C mutations
    Cho, B. C.
    Lu, S.
    Lee, M. A.
    Song, Z.
    Park, J. J. W.
    Lim, S. M.
    Li, Z.
    Zhao, J.
    Richardson, G.
    Zhang, Y.
    Zhang, J.
    Liu, A.
    Chen, C.
    Wang, J.
    Chen, J.
    Wang, A.
    Zhang, J.
    Chen, Z. G.
    Mok, T. S. K.
    Johnson, M. L.
    ANNALS OF ONCOLOGY, 2024, 35 : S493 - S493
  • [2] D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, overcomes nucleotide cycling and demonstrates robust preclinical and clinical activities
    Zhang, Jing
    Lim, Sun Min
    Yu, Mi Ra
    Chen, Cheng
    Wang, Jia
    Wang, Wenqian
    Rui, Haopeng
    Lu, Jingtao
    Lu, Shun
    Mok, Tony
    Chen, Zhi Jian
    Cho, Byoung Chul
    CANCER RESEARCH, 2024, 84 (06)
  • [3] Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumors
    Wang, J.
    Zhao, J.
    Zhong, J.
    Li, X.
    Fang, J.
    Yu, Y.
    Li, X.
    Fang, X.
    Chang, J.
    Liu, Z.
    Zhao, Y.
    Song, Q.
    Bai, C.
    Wang-Gillam, A.
    Ding, Y.
    Rao, Z.
    Bi, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S459 - S459
  • [4] Pan-tumor activity of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in patients with KRAS G12C-mutant advanced solid tumors.
    Heist, Rebecca Suk
    Koyama, Takafumi
    Murciano-Goroff, Yonina R.
    Hollebecque, Antoine
    Cassier, Philippe Alexandre
    Han, Ji-Youn
    Tosi, Diego
    Sacher, Adrian G.
    Burns, Timothy F.
    Spira, Alexander I.
    Gomez-Roca, Carlos A.
    Shimizu, Toshio
    Ammakkanavar, Natraj Reddy
    Sabari, Joshua K.
    Nagasaka, Misako
    Fink, Aaron Alan
    Chen, Aaron
    Willard, Melinda D.
    Oxnard, Geoffrey R.
    Kuboki, Yasutoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Second-Generation Atroposelective Synthesis of KRAS G12C Covalent Inhibitor GDC-6036
    Xu, Jie
    Lim, Ngiap-Kie
    Timmerman, Jacob C.
    Shen, Jeff
    Clagg, Kyle
    Orcel, Ugo
    Bigler, Raphael
    Trachsel, Etienne
    Meier, Roland
    White, Nicholas A.
    Burkhard, Johannes A.
    Sirois, Lauren E.
    Tian, Qingping
    Angelaud, Remy
    Bachmann, Stephan
    Zhang, Haiming
    Gosselin, Francis
    ORGANIC LETTERS, 2023, 25 (19) : 3417 - 3422
  • [6] Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models
    Nakayama, Ayako
    Nagashima, Takeyuki
    Nishizono, Yoshihiro
    Kuramoto, Kazuyuki
    Mori, Kenichi
    Homboh, Kazuya
    Yuri, Masatoshi
    Shimazaki, Masashi
    BRITISH JOURNAL OF CANCER, 2022, 126 (05) : 744 - 753
  • [7] Targeting the KRAS G12C Mutation in Patients With Advanced Solid Tumors
    Hong, David S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 612 - 614
  • [8] Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
    Choi, Yoonha
    Dharia, Neekesh V.
    Jun, Tomi
    Chang, Julie
    Royer-Joo, Stephanie
    Yau, Kenneth K.
    Assaf, Zoe J.
    Aimi, Junko
    Sivakumar, Smruthy
    Montesion, Meagan
    Sacher, Adrian
    LoRusso, Patricia
    Desai, Jayesh
    Schutzman, Jennifer L.
    Shi, Zhen
    CLINICAL CANCER RESEARCH, 2024, 30 (17) : 3788 - 3797
  • [9] Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation
    Patel, M.
    Lee, J-S.
    De Miguel, M. J.
    Burns, T.
    Falcon Gonzalez, A.
    Kim, T. W.
    Krebs, M. G.
    Prenen, H.
    Shmueli, E. Shacham
    Desai, J.
    Lorusso, P.
    Sacher, A.
    Choi, Y.
    Dharia, N.
    Lin, M. T.
    Mandlekar, S.
    Royer-Joo, S.
    Schutzman, J. L.
    Garralda, E.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S749 - S749
  • [10] Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models
    Ayako Nakayama
    Takeyuki Nagashima
    Yoshihiro Nishizono
    Kazuyuki Kuramoto
    Kenichi Mori
    Kazuya Homboh
    Masatoshi Yuri
    Masashi Shimazaki
    British Journal of Cancer, 2022, 126 : 744 - 753
12345